Regentis Biomaterials

Regentis Biomaterials is a tissue repair company focused on developing and commercializing of innovative hydrogel platform for the repair of damaged tissue. The Gelrin hydrogel platform is the foundation for the company’s flagship product, GelrinC, a biodegradable implant for cartilage regeneration. The product received ISO certification and is currently undergoing clinical trials in Germany, Belgium and Israel.

Regentis is funded by Crossroad Fund, Medica Venture Partners, SPCVitalife, DSM Ventures and the Technion Investment Opportunities Fund.


Back to Portfolio